Aclaris therapeutics reports second quarter 2023 financial results and provides a corporate update

- completion of enrollment in zunsemetinib phase 2b trial in rheumatoid arthritis as previously announced; data expected in q4 2023 -

ACRS Ratings Summary

ACRS Quant Ranking